drugset
drugset / Trial / NCT02672995

Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial

NCT02672995 ↗

Phase 1 Unknown 36 enrolled National Taiwan University Hospital
NaSingle-groupOpen-labelTreatment

Summary

The investigators propose a new treatment strategy of fractionated stereotactic radiosurgery with concurrent bevacizumab for brain metastases. This phase I dose-escalation study is to establish the feasibility of this strategy and find the recommended doses.

Timeline

Start
2018-01
Primary completion
2018-12
Completion
2018-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg —

Indications

brain neoplasm